Amarillo Bioscience Partner, CytoPharm, to Conduct 144 Patient Phase 2 Hepatitis C Trial in Taiwan

[Guest guest]

Amarillo Bioscience Partner, CytoPharm, to Conduct 144 Patient Phase 2 Hepatitis

C Trial in Taiwan

Market Wire - Feb. 19, 2008

AMARILLO, TX, February 19 / MARKET WIRE/ --

Amarillo Biosciences, Inc.(OTCBB: AMAR) today announced that the U.S. Food and

Drug Administration has allowed the Investigational New Drug (IND) application

submitted by the Company to test its low dose oral interferon in a Phase 2

hepatitis C clinical trial to go into effect. Accordingly, CytoPharm Inc., the

Company's partner in Taiwan, will fund and conduct a clinical trial of 144

chronic hepatitis C patients in Taiwan. The patients will receive one of two

different dosages of oral human interferon alpha or placebo.

The aim of the trial is to reduce relapse rate for those patients who have

completed the standard combination therapy, consisting of high dose injectable

interferon alpha and Ribavirin given orally. Although most patients respond to

the standard therapy, up to 40% of those with certain viral genotypes relapse

after treatment. The trial is expected to start in the 2nd quarter of 2008.

Approximately 170 million people are chronically infected with hepatitis C virus

worldwide. The incidence of cirrhosis in chronic hepatitis C patients is 10% to

20% and 1% to 5% develop liver cancer. Infections are transmitted primarily by

direct contact with blood through transfusions not screened for hepatitis C

virus, inadequately sterilized needles and syringes, sexual and perinatal

transmission. There is no effective vaccine against hepatitis C virus.

In addition to studies on hepatitis C, under the terms of the License and Supply

Agreement, CytoPharm will be testing oral interferon in human studies of chronic

active hepatitis B and influenza.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global

partnership with the Hayashibara Group, which also holds 11% of Amarillo

Biosciences shares and has provided over $18 million in loans, grants and equity

investments. The Company's primary focus is extensive and ongoing R & D into the

use of low-dose, orally administered interferon as a treatment for a variety of

conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic

infections in patients who are HIV positive. In its 23-year history, the Company

has invested nearly $39 million to establish oral interferon as a therapeutic

agent. The majority of those funds were invested in clinical trials in an effort

to achieve FDA approval for interferon. Additional information is available on

the web site at http://www.amarbio.com/.

About CytoPharm

CytoPharm is a closely held company focusing on the development of

biopharmaceuticals for virus-infected diseases and cancers. It was founded in

2002 by Ho Tung Chemical, Vita Genomics, and banks and venture capital firms. It

acquired core technologies from Gene Trol Therapeutics, Inc., a California based

company through M & A. Its product pipelines contain a series of cytokines induced

by its proprietary technologies, used for hepatitis, and cancers. Currently, its

product is under clinical trials in China. Both CytoPharm and Vita Genomics are

affiliates of Ho Tung Chemical Inc., one of the largest petrochemical companies

in Taiwan, and a publicly traded company whose 2006 revenues were approximately

NTD 39 billion.

Except for the historical information contained herein, the matters discussed in

this news release are forward-looking statements that involve risks and

uncertainties, including uncertainties related to product development,

uncertainties related to the need for regulatory and other government approvals,

dependence on proprietary technology, uncertainty of market acceptance of oral

interferon or the Company's other product candidates and other risks detailed

from time to time in the Company's filings with the Securities and Exchange

Commission. In particular, see " Item 1. Description of Business " of the

Company's Form 10-KSB for the year ended December 31, 2006.

Investor Relations:

Philippe Niemetz

PAN Consultants, Ltd.

e-mail: p.niemetz@...

Tel: 800-477-7570

212-344-6464

Fax: 212-618-1276

ph M. Cummins, DVM, PhD

Amarillo Biosciences, Inc.

e-mail: jcummins@...

Tel: 806-376-1741 x 13

Fax: 806-376-9301

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1727032 & contentty\

pe=sentryarticle & channelID=31

_________________________________________________________________

Helping your favorite cause is as easy as instant messaging. You IM, we give.

http://im.live.com/Messenger/IM/Home/?source=text_hotmail_join